Funding sources This study was supported by NIH/NIAMS Grant R01 AR28450 (J.U.) and K08 AR057099 (Q.J.). Dr Li Q.L. is the recipient of a Research Career Development Award from the Dermatology Foundation.
Paediatric pseudoxanthoma elasticum with cardiovascular involvement
Article first published online: 31 OCT 2013
© 2013 British Association of Dermatologists
British Journal of Dermatology
Volume 169, Issue 5, pages 1148–1151, November 2013
How to Cite
Li, Q., Baker, J., Kowalczyk, J., Jiang, Q., Uitto, J. and Schachner, L. (2013), Paediatric pseudoxanthoma elasticum with cardiovascular involvement. British Journal of Dermatology, 169: 1148–1151. doi: 10.1111/bjd.12462
Conflicts of interest None declared.
Q.L. and J.B. contributed equally to this study.
- Issue published online: 31 OCT 2013
- Article first published online: 31 OCT 2013
- Accepted manuscript online: 8 JUN 2013 12:40AM EST
- Manuscript Accepted: 2 JUN 2013
- NIH/NIAMS. Grant Number: R01 AR28450
Pseudoxanthoma elasticum (PXE) is characterized by aberrant mineralization of connective tissues, causing considerable morbidity and mortality. The disease is typically of late onset, the skin manifestations first being noted in the teens or later. Another aberrant mineralization disorder, generalized arterial calcification of infancy (GACI), is present at birth and can demonstrate a phenotypic overlap with PXE.
A patient with PXE was noted to have skin findings as early as at 6 years of age, with cardiovascular involvement. The purpose of this study was to examine the genetic basis of this phenotypic presentation in the spectrum of PXE/GACI.
The patient's genotype was studied by sequencing ABCC6 and ENPP1, genes known to be associated with PXE and/or GACI.
Screening of the ABCC6 gene revealed two pathogenetic mutations, p.R1141X and g.del23–29. Analysis of the ENPP1 gene failed to demonstrate the presence of mutations.
This study demonstrates the presence of cutaneous findings of PXE in an 8-year-old paediatric patient, with cardiovascular involvement, illustrating the phenotypic spectrum of PXE.